Management of Hyperalbuminuria

Introduction to Hyperalbuminuria Management

• The American College of Cardiology recommends starting all adults with hyperalbuminuria (albumin-to-creatinine ratio ≥30 mg/g) immediately on an SGLT2 inhibitor combined with a RAS inhibitor (ACE inhibitor or ARB), titrated to maximum tolerated dose, regardless of blood pressure or diabetes status 1, 2

SGLT2 Inhibitor Therapy

• The American Diabetes Association suggests starting dapagliflozin 10 mg daily or canagliflozin 100 mg daily immediately for all patients with eGFR ≥20 mL/min/1.73 m², even in non-diabetic patients with microalbuminuria 1, 3
• SGLT2 inhibitors provide kidney protection, reduce cardiovascular events, and decrease albuminuria independent of glucose-lowering effects 2
• Continue SGLT2 inhibitors even as eGFR declines below 20 mL/min/1.73 m² until dialysis or transplantation 1

RAS Inhibition

• The American Heart Association recommends starting an ACE inhibitor or ARB in all patients with albuminuria ≥30 mg/g, regardless of blood pressure status 4, 5, 2
• For patients with hypertension and albuminuria, ACE inhibitors or ARBs are mandatory first-line antihypertensive agents 4, 6
• Titrate to maximum tolerated dose (not just blood pressure control) for optimal kidney and cardiovascular protection 4, 1
• Monitor serum creatinine and potassium within 2-4 weeks after initiation or dose changes 4, 2

RAS Inhibitor Monitoring Protocol

• Continue therapy if creatinine increases <30% from baseline 4
• If creatinine rises >30%, hold temporarily and investigate for acute kidney injury, volume depletion, or NSAID use 4
• For hyperkalemia (K+ >5.5 mEq/L), implement potassium-lowering measures: dietary restriction, diuretics, sodium bicarbonate if acidotic, or gastrointestinal cation exchangers before discontinuing RAS inhibition 4
• Never combine ACE inhibitors with ARBs—this increases harm without additional benefit 4, 2

Blood Pressure Target

• The American Diabetes Association recommends targeting blood pressure <130/80 mmHg for all patients with diabetes and CKD 7, 8, 2
• For severely elevated albuminuria (≥300 mg/g), consider even lower targets (<130/80 mmHg) 8, 2
• Reduce blood pressure variability, as this independently predicts CKD progression 6

Nonsteroidal Mineralocorticoid Receptor Antagonist

• Add finerenone for patients already on maximum tolerated RAS inhibition with persistent albuminuria and eGFR ≥25 mL/min/1.73 m² 4, 1
• Finerenone provides additive kidney and cardiovascular protection beyond SGLT2 inhibitors and RAS blockade 4, 1
• Monitor potassium closely when adding to RAS inhibition 7

Glycemic Control

• The American Diabetes Association recommends targeting HbA1c of 7% to delay onset and progression of albuminuria 8, 6, 2
• Intensive glucose control reduces albuminuria and slows eGFR decline in both type 1 and type 2 diabetes 8

Lifestyle Modifications

• Restrict sodium to <2 g/day (<90 mmol/day or <5 g sodium chloride/day) 7, 1, 2
• Limit protein intake to 0.8 g/kg/day (the recommended daily allowance) 7, 1, 2
• Higher protein intake (>1.3 g/kg/day) increases albuminuria and accelerates kidney function loss 7
• Target BMI 20-25 kg/m² through weight management 1
• Smoking cessation is essential, as tobacco accelerates CKD progression 4

Statin Therapy

• Initiate moderate-to-high intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg daily) for all patients ≥50 years with CKD, regardless of baseline lipid levels 1, 2
• Statins reduce cardiovascular events and mortality in CKD patients 2

Monitoring Schedule

• Monitor urinary albumin-to-creatinine ratio and eGFR 2
• Annually for early CKD (eGFR >60 mL/min/1.73 m²) 7, 6
• Every 6-12 months for stage G3 CKD (eGFR 30-59 mL/min/1.73 m²) 7
• Every 3-5 months for stage G4 CKD (eGFR 15-29 mL/min/1.73 m²) 7
• Every 1-3 months for stage G5 CKD (eGFR <15 mL/min/1.73 m²) 7
• Monitor serum potassium in all patients on RAS inhibitors, especially with eGFR <60 mL/min/1.73 m² 7

Nephrology Referral

• Refer immediately when eGFR <30 mL/min/1.73 m² 1
• Refer immediately for persistent electrolyte abnormalities despite management 1
• Refer immediately for uncontrolled hypertension despite multiple agents 1
• Refer immediately for rapid decline in eGFR (>5 mL/min/1.73 m² per year) 7

Critical Medications to AVOID

• NSAIDs—increase acute kidney injury risk and blunt RAS inhibitor effectiveness 4, 1
• Metformin when eGFR <30 mL/min/1.73 m²—risk of lactic acidosis 8, 1
• Dual RAS blockade (ACE inhibitor + ARB)—increases harm without benefit 4, 2

Common Pitfalls

• Do not wait for hypertension to develop before starting RAS inhibition in patients with albuminuria 4, 5
• Do not use urine dipstick for screening—it misses microalbuminuria 9
• Do not discontinue RAS inhibitors for creatinine increases <30% 4
• Do not overlook cardiovascular disease management 2